Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025

加齢黄斑変性(AMD)及びその他の網膜疾患治療薬の世界市場:滲出型(ウェット型)、萎縮型(ドライ型)、糖尿病性網膜症

◆タイトル:Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025
◆商品コード:VGAIN503045
◆調査・発行会社:visiongain
◆発行日:2015年2月
◆ページ数:162
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥266,252見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、加齢黄斑変性(AMD)及びその他の網膜疾患治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・加齢黄斑変性(AMD)及びその他の網膜疾患治療薬の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・滲出型(ウェット型)加齢黄斑変性治療薬市場
・萎縮型(ドライ型)加齢黄斑変性治療薬市場
・糖尿病性網膜症治療薬市場
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Analysis of revenues and R&D prospects for those eye drugs – you explore potentials
What’s the future for treating disorders of the retina? Visiongain’s updated study forecasts those pharma revenues. There you find outlooks for sales growth in that industry. You also explore trends, technologies, therapies and opportunities.

That report gives revenue predictions to 2025 at overall world market, submarket, product and national level. So avoid falling behind in data or losing influence. Instead find what’s happening for those eye medicines. Discover, from 2015, what’s possible.

There gain technological, clinical and commercial outlooks. Read on to explore those ophthalmic pharmaceuticals and see what future revenues they could generate.

Forecasts and other analysis to benefit your research, assessments, plans and decisions
There explore prospects for companies developing, producing and marketing drugs for wet age-related macular degeneration (AMD or ARMD), dry AMD, diabetic retinopathy (DR) and other rear eye disorders. Discover present trends and future possibilities.

Besides revenue forecasting to 2025, our new work shows recent results, sales growth rates and market shares. There you find original analysis. Explore research and development too, seeing prospects. Also get 42 tables, 46 charts and two research interviews.

That survey also covers geographic atrophy (GA), diabetic macular oedema/edema (DME), proliferative and non-proliferative diabetic retinopathy (PDR and NPDR) and retinal vein occlusion (RVO). Avoid missing out on original data and discussions to help your work.

Ophthalmic technology – find sales growth opportunities and how to help your work
Stay ahead, then, in knowledge. Our study’s purpose is to benefit your research, analyses and decisions.

There find the most promising and lucrative treatments for neovascularisation and other retinal diseases from 2015.

The future holds great promise for organisations treating those rear eye disorders. Discover the progress and high gains possible there, avoiding struggles to find business information you need. See how patients, healthcare providers and companies can benefit.

And the following sections explain what you get in that new investigation.

Forecasting the world market and segments for medicines treating retinal disorders
What’re the secrets of that technology’s progress? What’s its potential? Find in our report overall world revenue to 2025 for retinal medicines – existing, emerging and expected drugs.

Also explore individual revenue predictions to 2025 for four therapeutic submarkets at world level:
• Wet age-related macular degeneration (wAMD)
• Dry AMD (dAMD)
• Diabetic retinopathy (DR)
• Other retinal diseases (grouped forecast).

Where lie the best prospects? You assess outlooks for revenue expansion, seeing where you can gain. And also investigate competitors’ actions and prospects.

There hear what’s happening for those ophthalmic medicines and discover where the money lies. Benefit your reputation for technological and commercial insight there, increasing your authority.

You also find sales predictions by product, exploring how they can succeed.

Predictions of leading products’ sales – what’s possible for those eye drug revenues?
How will individual retinal medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of five prominent brands:
• Lucentis
• Eylea
• Avastin
• Visudyne
• Jetrea.

There you discover how high sales can go, finding agents and years with highest predicted revenues. Also examine competition. That way you investigate what’s happening, understanding challenges, trends, competitors and opportunities.

Single and combination treatments hold importance. Our report explains. That work also shows you geographical predictions, by country.

Healthcare in national markets – what outlooks for retinal medical sales?
Advances in biotechnology and pharmaceuticals expand use of drugs to treat back-of-eye impairments and vision loss. Discover those technologies’ international sales prospects.

Our work shows you individual revenue forecasts to 2025 for 11 national markets:
• United States (US)
• Japan
• Germany, France, the UK, Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC countries).

There find countries with highest revenues and potential growth. You explore outlooks for treating ocular problems, serving doctors’ and patients’ needs. Assess opportunity and ways to help people retain eyesight. Discover, then, what’s possible for you and your organisation.

You also examine developments leading to novel treatments.

R&D for those ophthalmic agents – developmental trends, innovations and progress
There you also investigate R&D, appraising technological, clinical and commercial possibilities.

In our study explore research and development in slowing vision loss and restoring sight. You examine these advances and others:
• Combination therapies, including neovascularisation disrupters
• Angiogenesis inhibition by blocking pericyte recruitment
• Anti-inflammatory mechanisms (inc. corticosteroids)
• Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis pathways)
• Monoclonal antibodies, mAb fragments, DARPins (designed ankyrin repeat proteins) and visual cycle modulators.

Explore other agents and possibilities, too, including these:
• Oligonucleotides and siRNA therapy
• Anti-integrin oligopeptide treatment
• Complement factor inhibition and serotonin modifiers
• Angiotensin receptor blockers and converting enzyme inhibitors
• Biosimilars and other follow-on biologicals and next generation therapeutics
• Regenerative medicine, neural stem cells (NSCs), cellular and gene therapies.

That R&D holds strength, variety and promise. See what’s possible for big pharma companies and specialists in biological drugs (biologics) and other biotechnologies.

There you investigate progress, assessing that industry’s participants and their futures.

Companies and overall 2019 market value – what revenues possible?
Our analyses forecast the world market for retinal drugs will reach $12.5bn in 2019. It will achieve strong revenue expansion from 2015 to 2025. You find how high sales can go.

You also see what companies hold most potential. Examine eye drug developers, producers and marketers, including these firms:
• Roche
• Novartis
• Bayer
• Regeneron
• Allergan
• Valeant.

【レポートの目次】

1. Report Overview
1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Overview of the AMD and Other Retinal Diseases Market, 2014-2025
2.1 Market to Make Rapid Strides to 2025
2.2 Lucentis Still Holds Over 60% of the Total Market
2.2.1 Novartis the Leading Presence in the Market
2.3 Which are the Most Significant Disease Areas for the Market?
2.3.1 Nearly 200 Million People with AMD?
2.3.2 Over 100 Million with DR
2.3.3 First RVO Estimates Suggest Patient Population of 16 Million
2.3.4 Wet AMD Still the Main Source of Revenues in the Market
2.4 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
2.5 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
2.6 DR: Coming Into Clinical Focus, with DME the Main Target
2.7 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
2.8 Projections for All Segments, 2014-2025

3. Approved Products in the AMD and Other Retinal Diseases Market, 2014-2025
3.1 Will the Current Products Dominate the Market Through 2025?
3.2 Lucentis: The Market Leader, But For How Long?
3.2.1 Shadow of Avastin Still Hangs Over Lucentis
3.2.2 CATT Study Results: Clinical Differences Still Have Yet to Emerge
3.2.3 Eylea: The Bigger Threat to Lucentis?
3.2.4 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
3.2.5 Improving Cost and Compliance for Lucentis
3.2.6 Will Loss of Physician Goodwill Harm Lucentis’ Growth?
3.2.7 Lucentis Revenue Forecast 2014-2025
3.3 Eylea: Pretender to the Throne?
3.3.1 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
3.3.2 First Wave of Eylea’s Expansion Finally Beginning to Break?
3.3.3 Into DME and Other New Indications
3.3.4 Zaltrap Targeting Solid Tumour Markets
3.3.5 How Far Can Eylea’s Momentum Carry It?
3.3.6 Eylea Revenue Forecast 2014-2025
3.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
3.4.1 Judicial Review Averted in the UK by Price Adjustment
3.4.2 Multiple Attempts to Block Off-Label Avastin Since 2007
3.4.3 Roche and Novartis Challenge CATT’s Headline Conclusions
3.4.4 Will Eylea/Zaltrap Affect Avastin’s Place in the Market?
3.4.5 Will Anything Dislodge Avastin from its Central Position?
3.4.6 Avastin Revenue Forecast, 2014-2025
3.5 Visudyne (Valeant/Novartis): Declining Sales Throughout the Forecast Period
3.5.1 Visudyne Revenue Forecast, 2014-2025
3.6 Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013
3.6.1 Jetrea Revenue Forecast, 2014-2025

4. Wet AMD Segment, 2014-2025
4.1 Eylea: The Segment’s Biggest Short-Term Driver
4.2 Pipeline for wAMD: The Leading Candidates
4.3 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
4.3.1 Three Phase 3 Trials to Confirm Fovista’s Outstanding Phase 2 Results
4.3.2 Ophthotech Goes Public to Fund Phase 3 Effort
4.3.3 Ophthotech Partners with Novartis for Fovista
4.3.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
4.3.5 The Move toward Combination Therapies
4.4 Other Growth Factor Targets in the Pipeline
4.4.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
4.4.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
4.4.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
4.4.4 iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
4.5 Conbercept (Chengdu Kanghong Biotech): The Other Phase 3 Candidate in wAMD
4.5.1 A Chinese Competitor: Where Will Conbercept Fit In?
4.5.2 Binding Affinity Comparable to Eylea
4.6 Do We Need New Anti-VEGFR Agents or Delivery Systems?
4.6.1 AGN-150998 DARPin (Allergan): Novel Protein With Extended Half-Life
4.6.2 ESBA 1008 (Alcon): Single-Chain Monoclonal Antibody Fragment
4.6.3 PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
4.6.4 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
4.6.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
4.6.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
4.7 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
4.7.1 Verisome System and IBI-30089 (Icon Bioscience)
4.7.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
4.8 Other Targets Under Investigation in wAMD Drug Development
4.8.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
4.8.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
4.8.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
4.8.4 First Ophthalmic Complement Factor Inhibitor, AL-78898A (Alcon), Misses Primary Endpoint
4.8.5 Factor C5: A More Promising Target Addressed by ARC1905 Aptamer (Ophthotech) and LFG316 (Novartis)
4.8.6 Integrins: Another Blockable Component of the Neovascularisation Cascade?
4.8.7 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
4.8.8 Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
4.8.9 Novel Anti-Angiogenic Treatments in Development: Ora Bio’s ORA102 and CoMentis’ ATG003
4.8.10 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
4.8.11 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
4.9 Regenerative Medicine Approaches
4.9.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
4.9.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
4.9.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes

5. Dry AMD Segment, 2014-2025
5.1 Dry AMD Segment to Emerge in the Forecast Period
5.2 Who Will Achieve the Big Breakthrough in Dry AMD?
5.3 MC-1101 (MacuCLEAR): Leading the Pack?
5.3.1 Increasing Choroidal Blood Flow with Repurposed Product
5.3.2 Novel Endpoints in Phase 3 Study
5.3.3 Can MacuCLEAR Make It?
5.4 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
5.4.1 Data Expected in July 2016
5.4.2 Other Visual Cycle Modulators
5.5 High Hopes for Complement Inhibition in Dry AMD
5.5.1 Lampalizumab (Roche): The Big News of ARVO 2013
5.5.1.1 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
5.5.2 AL-78898A (Alcon): Phase 2 Trial in Dry AMD Terminated
5.5.3 Soliris (Alexion): Out of the Running?
5.6 Corticosteroids: Targeting Inflammation’s Role in Dry AMD Pathogenesis
5.6.1 Medidur Fluocinolone Acetonide (Alimera Sciences): Insert in Phase 2
5.6.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
5.7 Neuroprotection: One of Modern Medicine’s Holy Grails
5.7.1 Tandospirone (Alcon): No News on Serotonin 1A Agonist
5.7.2 NT-501 (Neurotech): Some Promising Data in Dry AMD Studies
5.7.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
5.7.4 RN6G (Pfizer): Amyloid Beta-Binding Monoclonal Antibody Still in Studies
5.7.5 VAR10200 (Varinel): A Preclinical Candidate to Watch
5.8 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
5.8.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
5.8.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
5.8.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
5.8.4 Biotime: Stem Cell leader with Dry AMD Interests
5.8.5 First iPSC Trial in Japan in Dry AMD Patients
5.8.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
5.9 Other Treatments for Dry AMD

6. Diabetic Retinopathy Segment, 2014-2025
6.1 Segment to Grow in Importance as Diabetes Epidemic Continues
6.2 DR Options Grow with DME Addressed by New Agents
6.3 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
6.4 Lucentis: The Game Changer for DR?
6.5 New Anti-VEGF Additions
6.5.1 Is Eylea Better than Lucentis and Avastin for DME?
6.6 Steroids in Development for DR
6.6.1 Iluvien (Alimera/pSivida): New Option in European Markets
6.6.2 A New Hope? Optina (Ampio Pharmaceuticals)
6.6.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
6.6.4 SK-0503 (Sanwa Kagaku Kenkyusho): Potential DME and BRVO Treatment
6.6.5 Cortiject (Santen): Prodrug Candidate
6.6.6 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
6.7 Other Products in Development for DR
6.7.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
6.7.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
6.7.3 TriLipix (Abbott): No New Development for Promising Drug
6.7.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
6.7.5 Darapladib (GlaxoSmithKline): Possible New Use for Atherosclerosis Drug
6.7.6 Jetrea (ThromboGenics/Novartis): Possibilities in DME?

7. Regional Market Breakdown, 2014-2025
7.1 Which Markets Hold the Most Revenue Growth Potential?
7.2 The US: Leading Market for Retinal Diseases
7.3 Japan: Strong Market Potential
7.4 EU5: Ageing Populations to Drive Market Growth
7.5 BRIC Nations: The Biggest Growth Driver for the Market

8. Qualitative Industry and Market Analysis, 2015-2025
8.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
8.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
8.3 Opportunities: New Markets and R&D Synergies
8.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
8.5 Social: Low Diagnosis, Low Compliance
8.6 Technological: Innovation for the Eye
8.7 Economic: Off-Label Treatment and Reimbursement Issues
8.8 Political: The Demography and Diabetes Challenges

9. Research Interviews
9.1 Interview with Philip G. Ralston, Jr., MacuCLEAR (Part 1)
9.1.1 MC-1101: Identifying and Treating Chiou Syndrome
9.1.2 Preventing Dry AMD Progression
9.1.3 Treating the Root Cause of Dry AMD
9.1.4 Phase 3: Endpoints and Prospects for MC-1101
9.2 Interview with Philip G. Ralston, Jr., MacuCLEAR (Part 2)
9.2.1 MC-1101: Progress in Clinical Trials
9.2.2 MC-1101 More Effective in Early to Mid-Range AMD
9.2.3 Partnerships and Expected Launch of MC-1101

10. Report Conclusions
10.1 The Age of Lucentis: Nearing Its Conclusion?
10.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
10.3 Indications Outside Wet AMD to Gain in Importance
10.4 Dry AMD Market Has Huge Potential
10.5 Fovista Most Prominent Among the Pipeline Candidates
10.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics

List of Tables
Table 1.1 Submarket Forecasts ($m) of AMD and Other Retinal Disease Therapies, 2014-2019
Table 1.2 Submarket Forecasts ($m) of AMD and Other Retinal Disease Therapies, 2019-2025
Table 1.3 Currency Exchange Rates: Average Exchange Rate to USD
Table 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 2.2 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 2.3 Market Breakdown by Product: Revenues ($m), Market Share (%), 2013
Table 2.4 Market Breakdown by Disease Segment: Revenues ($m), Market Share (%), 2013
Table 2.5 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2014
Table 2.6 Retinal Diseases Market Forecasts by Segment: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 2.7 Retinal Diseases Market Forecasts by Segment: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 2.8 Market Breakdown by Disease Segment: Revenues ($m), Market Share (%), 2019
Table 2.9 Market Breakdown by Disease Segment: Revenues ($m), Market Share (%), 2025
Table 3.1 Market Forecast by Leading Product: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 3.2 Market Forecast by Leading Product: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 3.3 Market Breakdown by Product: Revenues ($m), Market Share (%), 2019
Table 3.4 Market Breakdown by Product: Revenues ($m), Market Share (%), 2025
Table 3.5 Lucentis, Eylea and Avastin: Comparison of Reported Characteristics
Table 3.6 Lucentis: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 3.7 Lucentis: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 3.8 Eylea Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 3.9 Eylea Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 3.10 Avastin Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 3.11 Avastin Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 3.12 Visudyne Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 3.13 Visudyne Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 3.14 Jetrea Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 3.15 Jetrea Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 4.1 Wet AMD Segment: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 4.2 Wet AMD Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2025
Table 4.3 Selected R&D Pipeline for wAMD, 2014
Table 5.1 Dry AMD Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 5.2 Dry AMD Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2025
Table 5.3 Selected R&D Pipeline for Dry AMD, 2014
Table 6.1 DR Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2014-2019
Table 6.2 DR Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2025
Table 6.3 Selected R&D Pipeline for DR, 2014
Table 7.1 Regional Breakdown: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 7.2 Regional Breakdown: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 7.3 EU5 Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 7.4 EU5 Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 7.5 BRIC Nations Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2019
Table 7.6 BRIC Nations Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2025
Table 8.1 Strengths and Weaknesses in the AMD and Other Retinal Diseases Market, 2015
Table 8.2 Opportunities and Threats in the AMD and Other Retinal Diseases Market, 2015
Table 8.3 Social, Technological, Economic and Political Factors Influencing the AMD and Other Retinal Diseases Pharmaceutical Market (STEP Analysis), 2015-2025

List of Figures
Figure 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenues ($m), 2014-2025
Figure 2.2 Market Breakdown by Product Revenues ($m), Market Share (%), 2013
Figure 2.3 Market Breakdown by Company: Market Share (%), 2013
Figure 2.4 Leading Causes of Blindness Worldwide, Proportion of Total (%), 2010
Figure 2.5 Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2010
Figure 2.6 Market Breakdown by Disease Segment: Revenues ($m), 2013
Figure 2.7 Wet AMD Disease Segment: Market Share (%), 2013
Figure 2.8 Dry AMD Disease Segment: Market Share (%), 2013
Figure 2.9 DR Disease Segment: Market Share (%), 2013
Figure 2.10 Other Retinal Diseases Segment: Market Share (%), 2013
Figure 2.11 Market Breakdown by Disease Segment: Market Share (%), 2019
Figure 2.12 Market Breakdown by Disease Segment: Market Share (%), 2025
Figure 2.13 Retinal Diseases Market Breakdown by Segment: Revenues ($m), 2014-2025
Figure 2.14 Retinal Diseases Market Breakdown by Segment: Revenues ($m), 2013, 2019 and 2025
Figure 3.1 Market Breakdown by Product: Revenues ($m), Market Share (%), 2019
Figure 3.2 Market Breakdown by Product: Revenues ($m), Market Share (%), 2025
Figure 3.3 Market Forecast by Product: Revenues ($m), 2014-2025
Figure 3.4 Market Breakdown by Product: Revenues ($m), 2013, 2019 and 2025
Figure 3.5 Drivers and Restraints for Lucentis, 2014
Figure 3.6 Lucentis: Revenues Forecast ($m), 2014-2025
Figure 3.7 Drivers and Restraints for Eylea, 2014
Figure 3.8 Eylea Forecast: Revenues ($m), 2014-2025
Figure 3.9 Drivers and Restraints for Avastin, 2014
Figure 3.10 Avastin Forecast: Revenues ($m), 2014-2025
Figure 3.11 Visudyne Forecast: Revenues ($m), 2014-2025
Figure 3.12 Jetrea Forecast: Revenues ($m), 2014-2025
Figure 4.1 Wet AMD Segment Forecast: Revenues ($m), 2014-2025
Figure 5.1 Dry AMD Segment Forecast: Revenues ($m), 2014-2025
Figure 6.1 DR Segment Forecast: Revenues ($m), 2014-2025
Figure 7.1 Regional Breakdown: Revenues ($m), 2014-2025
Figure 7.2 Regional Breakdown: Revenues ($m), 2013, 2019 and 2025
Figure 7.3 Regional Market Share (%), 2013
Figure 7.4 Regional Market Share (%), 2019
Figure 7.5 Regional Market Share (%), 2025
Figure 7.6 US Market: Revenues ($m), 2014-2025
Figure 7.7 Japan: Revenues ($m), 2014-2025
Figure 7.8 EU5: Grouped Revenues ($m), 2014-2025
Figure 7.9 EU5 Breakdown: Revenues ($m), 2013-2025
Figure 7.10 EU5 Breakdown: Market Share (%), 2013
Figure 7.11 EU5 Breakdown: Market Share (%), 2019
Figure 7.12 EU5 Breakdown: Market Share (%), 2025
Figure 7.13 BRIC Nations Forecast: Revenues ($m), 2014-2025
Figure 7.14 BRIC Nations Forecasts: Revenues ($m), 2014-2025
Figure 7.15 Market Share (%) within BRIC Group by Country, 2013
Figure 7.16 Market Share (%) within BRIC Group by Country, 2019
Figure 7.17 Market Share (%) within BRIC Group by Country, 2025

【レポートのキーワード】

加齢黄斑変性(AMD)、網膜疾患、滲出型(ウェット型)加齢黄斑変性、萎縮型(ドライ型)加齢黄斑変性、糖尿病性網膜症、治療薬、製薬、医薬品

★調査レポート[加齢黄斑変性(AMD)及びその他の網膜疾患治療薬の世界市場:滲出型(ウェット型)、萎縮型(ドライ型)、糖尿病性網膜症] ( Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025 / VGAIN503045) 販売に関する免責事項
[加齢黄斑変性(AMD)及びその他の網膜疾患治療薬の世界市場:滲出型(ウェット型)、萎縮型(ドライ型)、糖尿病性網膜症] ( Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025 / VGAIN503045) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆